Subject(s)
Germinoma/physiopathology , Testicular Neoplasms/physiopathology , Testis/physiology , Adult , Chorionic Gonadotropin/metabolism , Fertility , Follicle Stimulating Hormone/metabolism , Follow-Up Studies , Germinoma/metabolism , Germinoma/therapy , Humans , Luteinizing Hormone/metabolism , Male , Retrospective Studies , Testicular Neoplasms/metabolism , Testicular Neoplasms/therapyABSTRACT
Results in 503 patients with germ cell testicular tumors treated between 1982 and 1992 were analyzed. A follow-up program for germ cell tumors is presented which is related to the individual risk of tumor relapse. The overall relapse rate was 7%, of which 82% had recurrent tumor within 1 year after treatment. A low risk of relapse (3-5%) is seen in patients with seminoma stage I and radiation and, usually, in early-stage patients treated with polychemotherapy. A moderate risk of relapse (6-11%) is observed in patients with non-seminoma stage I and lymphadenectomy without chemotherapy. Seminoma without radiation and non-seminoma without lymphadenectomy in clinical stage I, non-seminoma stage IIa and IIb without adjuvant chemotherapy after lymphadenectomy, and primary high tumor mass present a high risk of relapse (> 11%). Tumor recurrence is localized mainly in lung and retroperitoneum. Most important in the follow-up are tumor marker and chest X-ray. During the first year examinations should take place every 3 months in the low-risk group and every 2 months in the moderate and high risk group. Computer tomography is only required in high-risk patients. Usually a 3-year follow-up is sufficient.
Subject(s)
Aftercare/methods , Neoplasms, Germ Cell and Embryonal/therapy , Testicular Neoplasms/therapy , Biomarkers, Tumor/blood , Chemotherapy, Adjuvant , Combined Modality Therapy , Follow-Up Studies , Humans , Lymph Node Excision , Male , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/therapy , Neoplasms, Germ Cell and Embryonal/mortality , Neoplasms, Germ Cell and Embryonal/pathology , Radiotherapy, Adjuvant , Risk Factors , Survival Rate , Testicular Neoplasms/mortality , Testicular Neoplasms/pathologyABSTRACT
The article describes analytical data for the screening and detection of nimetazepam and its major metabolites. The methods comprise thin-layer chromatography, gas chromatography, UV-spectrophotometry, infrared- and mass spectrometry.
Subject(s)
Chromatography, Thin Layer , Hypnotics and Sedatives , Nitrazepam/analogs & derivatives , Substance Abuse Detection/methods , Humans , Nitrazepam/chemistry , Nitrazepam/pharmacokineticsABSTRACT
The paper describes a sensitive screening procedure for 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4- benzodiazepine-2-thione (quazepam, Oniria, Quazium) and its major metabolites.
Subject(s)
Anti-Anxiety Agents/blood , Benzodiazepines/blood , Anti-Anxiety Agents/metabolism , Benzodiazepines/metabolism , Biotransformation , Chromatography, Gas , Humans , Mass Spectrometry , Spectrophotometry, Infrared , Spectrophotometry, UltravioletABSTRACT
The paper describes a sensitive method for the detection of 7-chloro-2,3-dihydro-5-phenyl-1-(2-propinyl)-1H-1,4-benzodiazepine -2-one (pinazepam, Domar) and its major metabolites.
